FidoCure®
FidoCure®, formerly known as The One Health Company, is a healthcare firm based in Palo Alto, CA, specializing in personalized medicine and genomic testing for canine cancer treatment.
Company Overview
FidoCure®, previously known as The One Health Company, is based in Palo Alto, CA, with a remote working model. The company operates in the healthcare industry, specifically within healthcare services. With a compact team of 14 members, FidoCure® focuses on providing personalized medicine platforms for canine cancer treatment. It leverages genomic testing to optimize cancer therapies, ensuring targeted treatment beyond conventional chemotherapy and radiation options.
Personalized Canine Cancer Treatment
FidoCure® leverages an AI-driven precision medicine platform to identify cancer-causing mutations in dogs. By using genomic testing in combination with tumor type data, the company suggests targeted therapies. This approach contrasts with standard chemotherapy and radiation, offering potentially more effective treatment options. Thousands of dogs have benefited from FidoCure® services, often when other treatments were exhausted.
Scientific Validation and Data
FidoCure® has built the largest proprietary cancer data set globally, encompassing 1.7 billion data points. The company's patient results are consistently published and validated in scientific journals, reflecting its ongoing commitment to scientific research and innovation in canine cancer treatment. This extensive data set underpins FidoCure®'s ability to provide highly personalized and effective treatments for canine cancer.
Collaborative Veterinary Network
FidoCure® collaborates with over 143 clinics and 180 veterinary oncologists across the United States. This network empowers veterinarians to perform genetic sequencing and apply targeted therapies for dogs suffering from cancer. By partnering closely with veterinary professionals, FidoCure® aims to transform the standard of care for canine cancer and make advanced treatment options more accessible.
Y-Combinator and Mission
FidoCure® participated in the W18 batch of Y-Combinator, a notable startup accelerator. Founded by dog lovers and scientists, the company is driven by a mission to make effective canine cancer treatment accessible. The focus remains steadfast on leveraging advanced genomic technologies and AI to identify personalized treatment options, ensuring a higher quality of life for dogs diagnosed with cancer.